Murine lung cancer induces generalized T-cell exhaustion

Journal of Surgical Research

Volumn 195, Issue 2, 2015, Pages 541-549

  Mittal, Rohit ^a   Chen, Ching Wen ^a   Lyons, John D ^a   Margoles, Lindsay M ^a   Liang, Zhe ^a   Coopersmith, Craig M ^a   Ford, Mandy L ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Immune dysregulation; Immunology; Inflammation; T lymphocyte

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; LIPOCORTIN 5; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; BTLA PROTEIN, MOUSE; IMMUNOGLOBULIN RECEPTOR; PDCD1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; LUNG CANCER; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T CELL EXHAUSTION; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; IMMUNOLOGY; LUNG TUMOR; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES;

EID: 84928592143     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2015.02.004     Document Type: Article

References (36)

1. M. Campoli, C.C. Chang, and S. Ferrone HLA class I antigen loss, tumor immune escape and immune selection Vaccine 20 Suppl 4 2002 A40
2. M.J. Smyth, G.P. Dunn, and R.D. Schreiber Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity Adv Immunol 90 2006 1
3. J. Krempski, L. Karyampudi, and M.D. Behrens Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer J Immunol 186 2011 6905
4. C.C. Preston, E.L. Goode, L.C. Hartmann, K.R. Kalli, and K.L. Knutson Immunity and immune suppression in human ovarian cancer Immunotherapy 3 2011 539
5. A.B. del Campo, J. Carretero, N. Aptsiauri, and F. Garrido Targeting HLA class I expression to increase tumor immunogenicity Tissue Antigens 79 2012 147
6. E.J. Wherry T cell exhaustion Nat Immunol 12 2011 492
7. R. Mittal, M. Wagener, and E.R. Breed Phenotypic T cell exhaustion in a murine model of bacterial infection in the setting of pre-existing malignancy PLoS One 9 2014 e93523
8. D.G. Remick Do not get sick when you are sick: the impact of comorbid conditions Crit Care Med 32 2004 2147
9. M.D. Williams, L.A. Braun, and L.M. Cooper Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care Crit Care 8 2004 R291
10. P.A. Danai, M. Moss, D.M. Mannino, and G.S. Martin The epidemiology of sepsis in patients with malignancy Chest 129 2006 1432
11. A.C. Fox, C.M. Robertson, and B. Belt Cancer causes increased mortality and is associated with altered apoptosis in murine sepsis Crit Care Med 38 2010 886
12. S.D. Blackburn, H. Shin, and W.N. Haining Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection Nat Immunol 10 2009 29
13. H.T. Khong, Q.J. Wang, and S.A. Rosenberg Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression J Immunother 27 2004 184
14. H.H. Schmidt, Y. Ge, and F.J. Hartmann HLA class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients Oncoimmunology 2 2013 e24962
15. J. Ye, C. Ma, and F. Wang Specific recruitment of gamma delta regulatory T cells in human breast cancer Cancer Res 73 2013 6137
16. T.L. Whiteside Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression Expert Opin Biol Ther 10 2010 1019
17. S. Ferrone, and T.L. Whiteside Tumor microenvironment and immune escape Surg Oncol Clin N Am 16 2007 755 viii
18. G. Chen, and L.A. Emens Chemoimmunotherapy: reengineering tumor immunity Cancer Immunol Immunother 62 2013 203
19. R.K. Jain Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers J Clin Oncol 31 2013 2205
20. P.K. Srivastava, and F. Duan Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges Cancer Immunol Immunother: CII 62 2013 967
21. C.M. Paulos, and C.H. June Putting the brakes on BTLA in T cell-mediated cancer immunotherapy J Clin Invest 120 2010 76
22. W. Hobo, W.J. Norde, and N. Schaap B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation J Immunol (Baltimore, Md: 1950) 189 2012 39
23. S. Karakatsanis, G. Bertsias, P. Roussou, and D. Boumpas Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: brief review Hematol Oncol 32 2014 113
24. B. Bengsch, B. Seigel, and M. Ruhl Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation PLoS Pathog 6 2010 e1000947
25. J. Fourcade, Z. Sun, and O. Pagliano CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1 Cancer Res 72 2012 887
26. S. Spranger, R.M. Spaapen, and Y. Zha Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells Sci Transl Med 5 2013 200ra116
27. X. Huang, F. Venet, and Y.L. Wang PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis Proc Natl Acad Sci U S A 106 2009 6303
28. N.J. Shubin, C.S. Chung, D.S. Heffernan, L.R. Irwin, S.F. Monaghan, and A. Ayala BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction J Leukoc Biol 92 2012 593
29. K. Chang, C. Svabek, and C. Vazquez-Guillamet Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis Crit Care 18 2014 R3
30. N.A. Hutchins, J. Unsinger, R.S. Hotchkiss, and A. Ayala The new normal: immunomodulatory agents against sepsis immune suppression Trends Mol Med 20 2014 224
31. J.N. Blattman, E.J. Wherry, S.J. Ha, R.G. van der Most, and R. Ahmed Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection J Virol 83 2009 4386
32. J.R. Larrubia, S. Benito-Martinez, and J. Miquel Bim-mediated apoptosis and PD-1/PD-L1 pathway impair reactivity of PD1(+)/CD127(-) HCV-specific CD8(+) cells targeting the virus in chronic hepatitis C virus infection Cell Immunol 269 2011 104
33. S. Yao, Y. Zhu, and L. Chen Advances in targeting cell surface signalling molecules for immune modulation Nat Rev Drug Discov 12 2013 130
34. S.V. Vaidya, S.E. Stepp, and M.E. McNerney Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells J Immunol 174 2005 800
35. B. Altvater, S. Landmeier, and S. Pscherer 2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells Cancer Immunol Immunother: CII 58 2009 1991
36. D. Liu, S.M. Krummey, and I.R. Badell 2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses J Exp Med 211 2014 297